Polaris Greystone Financial Group LLC Acquires 1,313 Shares of Johnson & Johnson (JNJ)

Polaris Greystone Financial Group LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 29.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,718 shares of the company’s stock after buying an additional 1,313 shares during the quarter. Polaris Greystone Financial Group LLC’s holdings in Johnson & Johnson were worth $738,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in JNJ. Vanguard Group Inc increased its position in shares of Johnson & Johnson by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after purchasing an additional 3,235,861 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after purchasing an additional 3,235,861 shares in the last quarter. Morgan Stanley increased its position in shares of Johnson & Johnson by 6.3% during the 3rd quarter. Morgan Stanley now owns 22,920,470 shares of the company’s stock worth $3,166,921,000 after purchasing an additional 1,352,484 shares in the last quarter. Royal London Asset Management Ltd. acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $150,576,000. Finally, Los Angeles Capital Management & Equity Research Inc. increased its position in shares of Johnson & Johnson by 58.2% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 1,602,167 shares of the company’s stock worth $221,371,000 after purchasing an additional 589,288 shares in the last quarter. Institutional investors own 67.32% of the company’s stock.

Shares of NYSE:JNJ opened at $138.02 on Wednesday. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47. The stock has a market cap of $370.29 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 2.21 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping analysts’ consensus estimates of $2.06 by $0.04. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The firm had revenue of $20.02 billion for the quarter, compared to analyst estimates of $19.55 billion. During the same quarter in the prior year, the firm earned $2.06 EPS. The company’s revenue was up .1% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 8.58 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “sell” rating in a research report on Tuesday, December 18th. Citigroup increased their target price on shares of Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a research report on Monday, February 25th. Morgan Stanley set a $140.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Thursday, December 20th. Barclays reiterated an “equal weight” rating and set a $135.00 target price (down previously from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Finally, Wells Fargo & Co reissued an “outperform” rating and set a $152.00 price objective (down previously from $162.00) on shares of Johnson & Johnson in a report on Monday, January 14th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus target price of $143.58.

ILLEGAL ACTIVITY WARNING: “Polaris Greystone Financial Group LLC Acquires 1,313 Shares of Johnson & Johnson (JNJ)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2019/04/17/polaris-greystone-financial-group-llc-acquires-1313-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: What is a Roth IRA?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit